| Literature DB >> 29066439 |
Erin Thomas1, Jie Yang2, Jianjin Xu3, Fabio V Lima1,4, Kathleen Stergiopoulos5.
Abstract
BACKGROUND: Pregnant women with pulmonary hypertension (PH) are at risk for adverse cardiac outcomes, particularly at the time of labor and delivery. The purpose of this study is to define the impact of PH on pregnancy outcomes and the risk of major adverse cardiac events (MACE). METHODS ANDEntities:
Keywords: cardiomyopathy; congenital heart disease; pregnancy; pulmonary hypertension
Mesh:
Year: 2017 PMID: 29066439 PMCID: PMC5721838 DOI: 10.1161/JAHA.117.006144
Source DB: PubMed Journal: J Am Heart Assoc ISSN: 2047-9980 Impact factor: 5.501
Figure 1Extraction of study population. This figure illustrates the manner in which records were extracted from the NIS data set. After extraction, there was a total of 1519 patients with PH and 6 757 582 patients without heart disease. HCUP NIS does not allow reporting of <10 events in order to protect individuals’ privacy. HCUP indicates Healthcare Cost and Utilization Project; NIS, National Inpatient Sample; PH, pulmonary hypertension.
Figure 2Prevalence of pregnancy and PH. This figure shows the breakdown of subclasses among the total 1519 patients with PH. CDM indicates cardiomyopathy; CHD, congenital heart disease; PH, pulmonary hypertension; VHD, valvular heart disease.
Characteristics of Women With and Without PH, and Associated Subtype
| Variable | PH (N=1519) | No Heart Disease (N=6 757 582) |
| Isolated PH (N=906) | PH+CHD (N=163) | PH+VHD (N=275) | PH+VHD+CHD (N=45) | PH+CDM (N=101) | PH+CDM+VHD (N=29) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Age at admission, y, n±SD | 30.1±6.3 | 28.1±5.9 | <0.0001 | 30.4±6.4 | 28.0±5.6 | 30.3±6.3 | 28.0±4.6 | 31.7±6.2 | 30.1±6.3 | <0.0001 |
| Race, n (%) | ||||||||||
| White | 552 (36.3) | 3 539 607 (52.3) | <0.0001 | 344 (38.0) | 54 (33.1) | 95 (34.6) | 15 (33.3) | 37 (36.7) | <10 | <0.0001 |
| Black | 460 (30.2) | 912 339 (13.5) | 304 (33.6) | 29 (17.8) | 71 (25.8) | <10 | 36 (35.6) | 14 (48.3) | ||
| Hispanic | 339 (22.3) | 1 583 335 (23.4) | 186 (20.5) | 56 (34.4) | 64 (23.3) | 18 (40.0) | 11 (10.9) | <10 | ||
| Asian or Pacific Islander | 75 (4.9) | 344 673 (5.1) | 30 (3.3) | 12 (7.4) | 23 (8.4) | <10 | <10 | <10 | ||
| Native American | 17 (1.1) | 50 894 (0.8) | <10 | <10 | <10 | 0 | <10 | 0 | ||
| Other | 76 (5.0) | 326 734 (4.8) | 34 (3.8) | 10 (6.1) | 20 (7.3) | <10 | <10 | <10 | ||
| Primary payer | ||||||||||
| Medicare | 59 (3.9) | 39 798 (0.6) | <0.0001 | 40 (4.4) | <10 | <10 | <10 | <10 | <10 | 0.3062 |
| Medicaid | 783 (51.6) | 2 853 438 (42.2) | 451 (49.8) | 87 (53.4) | 147 (53.45) | 27 (60.00) | 53 (52.48) | 18 (62.07) | ||
| Private including HMO | 571 (37.6) | 3 446 689 (51.0) | 357 (39.4) | 59 (36.2) | 99 (36.0) | 11 (24.4) | 37 (36.6) | <10 | ||
| Self‐pay | 41 (2.7) | 234 407 (3.5) | 19 (2.1) | <10 | 12 (4.4) | <10 | <10 | 0 | ||
| No charge | 14 (0.9) | 17 705 (0.3) | <10 | <10 | <10 | <10 | <10 | 0 | ||
| Other | 51 (3.4) | 165 545 (2.5) | 34 (3.8) | <10 | <10 | 0 | <10 | <10 | ||
| Length of stay, d | 6.7±8.8 | 2.7±2.6 | <0.0001 | 6.3±7.8 | 6.3±10.8 | 7.2±9.5 | 7.7±12.3 | 8.6±9.3 | 7.9±10.6 | 0.1446 |
| Total charges, in dollars | 41 171.3±74 258.1 | 12 036.7±12 275.8 | <0.0001 | 37 977.4±59 355.1 | 45 362.7±121 932.3 | 40 539.7±66 112.6 | 58 803.8±131 359.5 | 49 815.1±58 943.1 | 68 512.1±129 877.1 | 0.2973 |
| Location/teaching status of hospital | ||||||||||
| Rural | 61 (4.1) | 650 583 (9.7) | <0.0001 | 41 (4.6) | <10 | <10 | <10 | <10 | 0 | 0.3325 |
| Urban nonteaching | 363 (24.1) | 2 952 479 (44.0) | 232 (26.0) | 30 (18.4) | 67 (24.5) | <10 | 21 (20.8) | <10 | ||
| Urban teaching | 1082 (71.9) | 3 114 281 (46.4) | 621 (69.5) | 127 (77.9) | 200 (73.0) | 36 (80.0) | 75 (74.3) | 23 (79.3) | ||
| Teaching hospital | 1143 (75.3) | 3 764 864 (55.7) | <0.0001 | 662 (73.1) | 133 (81.6) | 207 (75.3) | 38 (84.4) | 80 (79.2) | 23 (79.3) | 0.1061 |
| Region of hospital | ||||||||||
| Northeast | 326 (21.5) | 1 324 827 (19.6) | <0.0001 | 203 (22.4) | 30 (18.4) | 66 (24.0) | 12 (26.7) | 12 (11.9) | <10 | 0.3192 |
| Midwest | 193 (12.7) | 962 383 (14.2) | 124 (13.7) | 18 (11.0) | 28 (10.2) | <10 | 13 (12.9) | <10 | ||
| South | 675 (44.4) | 2 712 729 (40.1) | 395 (43.6) | 77 (47.2) | 124 (45.1) | 20 (44.4) | 47 (46.5) | 12 (41.4) | ||
| West | 325 (21.4) | 1 757 643 (26.0) | 184 (20.3) | 38 (23.3) | 57 (20.7) | <10 | 29 (28.7) | <10 | ||
| Comorbidities | ||||||||||
| Diabetes mellitus | 84 (5.5) | 69 130 (1.0) | <0.0001 | 65 (7.2) | <10 | <10 | 0 | 10 (9.9) | <10 | 0.0004 |
| Gestational diabetes mellitus | 52 (3.4) | 46 943 (0.7) | <0.0001 | 45 (5.0) | 0 | <10 | 0 | <10 | <10 | 0.0071 |
| Multiple gestation | 75 (4.9) | 127 693 (1.9) | <0.0001 | 54 (6.0) | 0 | 15 (5.5) | 0 | <10 | <10 | 0.0238 |
| Systemic lupus erythematosus | 29 (1.9) | 7413 (0.1) | <0.0001 | 23 (2.5) | <10 | <10 | 0 | <10 | <10 | 0.0508 |
| Systemic sclerosis | <10 | 359 (0.0) | <0.0001 | <10 | 0 | <10 | 0 | 0 | 0 | 0.7184 |
| Rheumatoid arthritis | <10 | 5330 (0.1) | <0.0001 | <10 | 0 | 0 | 0 | 0 | 0 | 0.7986 |
| Sickle cell disease | 11 (0.7) | 1970 (0.0) | <0.0001 | <10 | <10 | <10 | 0 | <10 | 0 | 1 |
| Thyroid disease | 0 | 3186 (0.1) | 0.3973 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Portal hypertension | <10 | 78 (0.0) | <0.0001 | <10 | 0 | 0 | 0 | 0 | 0 | 0.8074 |
| Chronic thromboembolic disease | 1335 (87.9) | 0 | <0.0001 | 771 (85.1) | 150 (92.0) | 255 (92.7) | 38 (84.4) | 93 (92.1) | 28 (96.6) | 0.0021 |
| HIV | <10 | 1839 (0.0) | <0.0001 | <10 | 0 | <10 | 0 | 0 | 0 | 1 |
| Obstructive sleep apnea | 45 (3.0) | 1590 (0.0) | <0.0001 | 39 (4.3) | 0 | <10 | <10 | <10 | <10 | 0.0142 |
| Preexisting hypertension | 110 (7.2) | 55 225 (0.8) | <0.0001 | 71 (7.8) | <10 | 13 (4.7) | <10 | 15 (14.9) | <10 | 0.0049 |
| Eisenmenger syndrome | 45 (3.0) | 0 | <0.0001 | 0 | 33 (20.3) | 0 | 12 (26.7) | 0 | 0 | <0.0001 |
CDM indicates cardiomyopathy; CHD, congenital heart disease; HIV, human immunodeficiency virus; HMO, health maintenance organization; PH, pulmonary hypertension; VHD, valvular heart disease.
P value was based on χ2 test for categorical variables and Welch test for continuous variables to compare healthy women and women with PH. Column percentage was reported.
P value was based on χ2 test with exact value from Monte Carlo simulation for categorical variables and Welch test for continuous variables. Column percentage was reported.
Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample does not allow reporting of <10 events in order to protect individuals’ privacy.
Prevalence of MACE, Respiratory and Renal Failure in Women With PH
| Variable | PH (N=1519) | No Heart Disease (N=6 757 582) |
| PH (N=906) | PH+CHD (N=163) | PH+VHD (N=275) | PH+VHD+CHD (N=45) | PH+CDM (N=101) | PH+CDM+VHD (N=29) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| MACE, n (%) | 376 (24.8) | 25 128 (0.4) | <0.0001 | 183 (20.2) | 25 (15.3) | 75 (27.3) | 15 (33.3) | 60 (59.4) | 18 (62.1) | <0.0001 |
| Mortality (maternal) | 12 (0.8) | 475 (0.0) | <0.0001 | 10 (1.1) | <10 | <10 | 0 | 0 | 0 | 0.6379 |
| Acute myocardial infarction | <10 | 181 (0.0) | <0.0001 | <10 | 0 | <10 | 0 | 0 | <10 | 0.1823 |
| Heart failure | 188 (12.4) | 1390 (0.0) | <0.0001 | 74 (8.2) | 11 (6.8) | 25 (9.1) | 10 (22.2) | 52 (51.5) | 16 (55.2) | <0.0001 |
| Arrhythmia | 175 (11.5) | 21 004 (0.3) | <0.0001 | 84 (9.3) | 15 (9.2) | 47 (17.1) | <10 | 20 (19.8) | <10 | 0.0013 |
| Cerebrovascular events | <10 | 583 (0.0) | <0.0001 | <10 | 0 | 0 | 0 | 0 | 0 | 1 |
| Arterial embolism | <10 | 53 (0.0) | <0.0001 | <10 | 0 | 0 | 0 | 0 | 0 | 1 |
| Obstetrical pulmonary embolism | 44 (2.9) | 1675 (0.0) | <0.0001 | 32 (3.5) | <10 | <10 | 0 | <10 | 0 | 0.3584 |
| Cardiac complications of anesthesia or other sedation in labor and delivery | <10 | 474 (0.0) | <0.0001 | <10 | 0 | <10 | 0 | 0 | 0 | 0.6353 |
| Cardiorespiratory shock | <10 | 313 (0.0) | <0.0001 | <10 | 0 | <10 | 0 | 0 | 0 | 0.4888 |
| Shock unspecified | 0 | 36 (0.0) | 0.9283 | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Cardiogenic shock | <10 | 35 (0.0) | <0.0001 | <10 | 0 | <10 | 0 | 0 | 0 | 0.2967 |
| Other shock without trauma | <10 | 242 (0.0) | <0.0001 | <10 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other non‐MACE outcome measures | ||||||||||
| Respiratory failure | 117 (7.7) | 4213 (0.1) | <0.0001 | 71 (7.8) | <10 | 20 (7.3) | <10 | 11 (10.9) | <10 | 0.3121 |
| Mechanical ventilation | 71 (4.7) | 3287 (0.1) | <0.0001 | 42 (4.6) | <10 | 10 (3.6) | <10 | 11 (10.9) | <10 | 0.0166 |
| Noninvasive positive pressure ventilation | 18 (1.2) | 534 (0.0) | <0.0001 | 13 (1.4) | <10 | <10 | 0 | 0 | <10 | 0.2936 |
| Acute renal failure | 26 (1.7) | 1978 (0.0) | <0.0001 | 17 (1.9) | 0 | <10 | <10 | <10 | <10 | 0.039 |
CDM indicates cardiomyopathy; CHD, congenital heart disease; MACE, major adverse cardiovascular events; PH, pulmonary hypertension; VHD, valvular heart disease.
P value was based on χ2 test for categorical variables and Welch test for continuous variables to compare healthy women and women with PH. Column percentage was reported.
P value was based on χ2 test with exact value from Monte Carlo simulation for categorical variables and Welch test for continuous variables. Column percentage was reported.
Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample does not allow reporting of <10 events in order to protect individuals’ privacy.
Figure 3MACE rates in pregnant women with pulmonary hypertension. This figure compares the MACE rates of women with PH and women without any heart disease, as well as the MACE rates among the PH subclasses. CDM indicates cardiomyopathy; CHD, congenital heart disease; MACE, major adverse cardiac events; PH, pulmonary hypertension; VHD, valvular heart disease.
Obstetric Outcomes in Women With PH During Hospitalization for Delivery
| Variable | PH (N=1519) | No Heart Disease (N=6 757 582) |
| PH (N=906) | PH+CHD (N=163) | PH+VHD (N=275) | PH+VHD+CHD (N=45) | PH+CDM (N=101) | PH+CDM+VHD (N=29) |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Transient HTN, n (%) | 47 (3.1) | 212 697 (3.2) | 0.9051 | 34 (3.8) | <10 | <10 | 0 | <10 | 0 | 0.0812 |
| Eclampsia status | ||||||||||
| Eclampsia | <10 | 4961 (0.1) | <0.0001 | <10 | <10 | 0 | 0 | <10 | 0 | 0.0099 |
| Severe preeclampsia | 102 (6.7) | 83 781 (1.2) | 65 (7.2) | <10 | 17 (6.2) | <10 | 10 (9.9) | <10 | ||
| Mild preeclampsia | 80 (5.3) | 147 957 (2.2) | 55 (6.1) | <10 | 10 (3.6) | <10 | <10 | <10 | ||
| Preeclampsia or eclampsia with preexisting HTN | 121 (8.0) | 33 202 (0.5) | 84 (9.3) | 10 (6.1) | 12 (4.4) | <10 | 12 (11.9) | <10 | ||
| Obstetric bleeding | 44 (2.9) | 116 052 (1.7) | 0.0004 | 26 (2.9) | <10 | <10 | 0 | <10 | 0 | 0.1838 |
| Postpartum hemorrhage | 90 (5.9) | 182 156 (2.7) | <0.0001 | 55 (6.1) | <10 | 13 (4.7) | <10 | <10 | <10 | 0.9037 |
| Postpartum infection | 47 (3.1) | 26 444 (0.4) | <0.0001 | 32 (3.5) | <10 | <10 | <10 | <10 | <10 | 0.4181 |
| Laceration | 13 (0.9) | 165 550 (2.5) | <0.0001 | <10 | <10 | <10 | <10 | 0 | <10 | 0.3946 |
| Premature rupture of membrane | 53 (3.5) | 260 156 (3.9) | 0.465 | 30 (3.3) | <10 | 11 (4.0) | <10 | <10 | <10 | 0.9343 |
| Preterm delivery | 327 (21.5) | 478 012 (7.1) | <0.0001 | 187 (20.6) | 29 (17.8) | 57 (20.7) | 10 (22.2) | 33 (32.7) | 11 (37.9) | 0.0148 |
| Intrauterine fetal demise | 19 (1.3) | 27 627 (0.4) | <0.0001 | 14 (1.6) | 0 | <10 | <10 | <10 | <10 | 0.0471 |
| Cesarean delivery | 755 (49.7) | 2 143 724 (31.7) | <0.0001 | 460 (50.8) | 71 (43.6) | 127 (46.2) | 22 (48.9) | 58 (57.4) | 17 (58.6) | 0.1837 |
| Vaginal delivery | ||||||||||
| Vaginal delivery alone | 759 (50.0) | 4 544 928 (67.3) | <0.0001 | 444 (49.0) | 91 (55.8) | 148 (53.8) | 23 (51.1) | 43 (42.6) | 10 (34.5) | 0.0183 |
| Vacuum assisted | <10 | 66 375 (0.9) | <10 | <10 | 0 | 0 | 0 | <10 | ||
| Failed vacuum | <10 | 2288 (0.0) | <10 | 0 | 0 | 0 | 0 | 0 | ||
CDM indicates cardiomyopathy; CHD, congenital heart disease; HTN, hypertension; PH, pulmonary hypertension; VHD, valvular heart disease.
P value was based on χ2 test for categorical variables and Welch test for continuous variables to compare healthy women and women with PH. Column percentage was reported.
P value was based on χ2 test with exact value from Monte Carlo simulation for categorical variables and Welch test for continuous variables. Column percentage was reported.
Healthcare Cost and Utilization Project (HCUP) National Inpatient Sample does not allow reporting of <10 events in order to protect individuals’ privacy.
Figure 4Multivariable analysis comparing individual predictors of MACE. Multivariable regression analysis was performed for those factors in which P<0.1 in univariate analysis. “PH and CHD” and “Northeast” were used as references for the disease type and hospital region analysis because they exhibited the lowest MACE rates in descriptive statistics. The following variables were independent predictors for MACE: PH and VHD (P=0.024), PH and VHD and CHD (P=0.0076), PH and CDM (P<0.0001), and PH and CDM and VHD (P<0.0001). CDM indicates cardiomyopathy; CHD, congenital heart disease; CI, confidence interval; HTN, hypertension; MACE, major adverse cardiac events; PH, pulmonary hypertension; VHD, valvular heart disease.